We are live on ! Find out more
MPM BioImpact

MPM BioImpact Portfolio holdings

AUM $1.35B Turnover 42.55%
1-Year Est. Return 172.14%
 

MPM BioImpact runs biotech venture, hybrid and hedge funds, and its impact funds put private and public money into companies aiming to change outcomes for patients with disease. Its hedge funds concentrate on small and mid-sized healthcare companies, while the firm as a whole combines MPM Capital's biotech venture capital record of more than 30 years with BioImpact's public investing. The firm was called MPM Oncology Impact Management until 2021 and BioImpact Capital until 2023. Ansbert Gadicke, its founder and managing partner, is also its controlling owner. Among its portfolio stories, it built the radiopharmaceutical company Aktis Oncology for solid tumors and was an early backer of argenx, an immunology company.

This Fund
S&P 500
This Quarter Est. Return
-11.01%
1 Year Est. Return
+172.14%
3 Year Est. Return
+619.29%
5 Year Est. Return
+756.25%
10 Year Est. Return
–
AUM
$645M
AUM Growth
+$36M
Cap. Flow
+$150M
Cap. Flow %
23.21%
Top 10 Hldgs %
72.39%
Holding
33
New
19
Increased
7
Reduced
3
Closed
–
Avg Time Held
0.6 years
Top 10 Avg Time Held
0.9 years
Top 20 Avg Time Held
0.9 years

Top Sells

Rank Stock Value
1
CGEM icon
Cullinan Therapeutics
CGEM
+$7.1M
2
ITOS icon
iTeos Therapeutics
ITOS
+$6.05M
3
RPTX icon
Repare Therapeutics
RPTX
+$1.17M

Sector Composition

Rank Sector Weight
1 Healthcare 94.65%
2 Miscellaneous 5.35%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow Held Since
CGEM icon
1
Cullinan Therapeutics
CGEM
$617M
$173M 26.78%
7,648,268
-265,619
-3% -$7.1M
2021 Q1
2 quarters
ITOS icon
2
DELISTED
iTeos Therapeutics
ITOS
$56.9M 8.82%
2,107,092
-231,489
-10% -$6.05M
2020 Q3
4 quarters
RPTX icon
3
DELISTED
Repare Therapeutics
RPTX
$43M 6.67%
1,639,849
-36,238
-2% -$1.17M
2020 Q2
5 quarters
HOWL icon
4
Werewolf Therapeutics
HOWL
$48.2M
$41M 6.36%
2,388,011
– –
2021 Q2
1 quarter
TCRR
5
DELISTED
TCR2 Therapeutics
TCRR
$28.7M 4.45%
3,370,982
– –
2019 Q4
7 quarters
HARP
6
DELISTED
Harpoon Therapeutics
HARP
$25.3M 3.92%
319,671
– –
2019 Q4
7 quarters
ONCR
7
DELISTED
Oncorus
ONCR
$22.2M 3.44%
2,377,031
– –
2020 Q4
3 quarters
NTLA icon
8
Intellia Therapeutics
NTLA
$1.37B
$21.8M 3.38%
+162,620
New +$24.6M
2021 Q3
0 quarters
MRUS icon
9
DELISTED
Merus
MRUS
$20.7M 3.21%
941,948
+241,069
+34% +$5.17M
2020 Q2
5 quarters
EPZM
10
DELISTED
Epizyme
EPZM
$20.3M 3.16%
3,972,830
+1,641,296
+70% +$10M
2019 Q4
7 quarters
TPTX
11
DELISTED
Turning Point Therapeutics
TPTX
$18M 2.8%
271,350
+2,164
+0.8% +$154K
2020 Q1
6 quarters
YMAB icon
12
DELISTED
Y-mAbs Therapeutics
YMAB
$12.9M 2.01%
452,970
+115,679
+34% +$3.65M
2019 Q4
7 quarters
GTHX icon
13
DELISTED
G1 Therapeutics
GTHX
$11.5M 1.79%
860,502
+47,708
+6% +$777K
2019 Q4
7 quarters
BCRX icon
14
BioCryst Pharmaceuticals
BCRX
$1.92B
$10.1M 1.57%
+704,767
New +$11.1M
2021 Q3
0 quarters
ADCT icon
15
ADC Therapeutics
ADCT
$176M
$9.36M 1.45%
344,519
+126,492
+58% +$3.24M
2020 Q2
5 quarters
CYTK icon
16
Cytokinetics
CYTK
$7.2B
$8.84M 1.37%
+247,291
New +$7.28M
2021 Q3
0 quarters
VSTM icon
17
Verastem
VSTM
$970M
$8.7M 1.35%
+235,405
New +$8.65M
2021 Q3
0 quarters
GERN icon
18
Geron
GERN
$607M
$7.85M 1.22%
+5,732,770
New +$7.65M
2021 Q3
0 quarters
TVTX icon
19
Travere Therapeutics
TVTX
$4.77B
$7.43M 1.15%
+306,515
New +$5.63M
2021 Q3
0 quarters
NEO icon
20
NeoGenomics
NEO
$1.99B
$7.21M 1.12%
+149,504
New +$6.92M
2021 Q3
0 quarters
CRNX icon
21
DELISTED
Crinetics Pharmaceuticals
CRNX
$6.28M 0.97%
+298,392
New +$6.24M
2021 Q3
0 quarters
MIRM icon
22
Mirum Pharmaceuticals
MIRM
$5.98B
$6.15M 0.95%
+308,532
New +$5.02M
2021 Q3
0 quarters
HRMY icon
23
Harmony Biosciences
HRMY
$1.94B
$5.81M 0.9%
+151,650
New +$4.88M
2021 Q3
0 quarters
EPIX icon
24
DELISTED
ESSA Pharma
EPIX
$5.47M 0.85%
+683,287
New +$10.9M
2021 Q3
0 quarters
FOLD icon
25
DELISTED
Amicus Therapeutics
FOLD
$5.22M 0.81%
+546,558
New +$5.59M
2021 Q3
0 quarters

Similar funds

MPM BioImpact's Q3 2021 Portfolio in Review

As of Q3 2021, MPM BioImpact held 33 positions worth $645M, up 5.9% from $609M the previous quarter. Its ten largest holdings account for 72% of the portfolio.

MPM BioImpact deployed $150M of net new capital in Q3 2021, opening 19 new positions and adding to 7 existing holdings. Its largest new stake was Intellia Therapeutics: 162,620 shares worth $21.8M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 95% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Cullinan Therapeutics, an estimated $7.1M trimmed.

  • MPM BioImpact's largest Q3 2021 buy was Intellia Therapeutics: 162,620 shares worth $21.8M.
  • MPM BioImpact added most to Epizyme in Q3 2021, an estimated $10M increase.
  • MPM BioImpact's biggest Q3 2021 reduction was Cullinan Therapeutics, cutting an estimated $7.1M.
  • MPM BioImpact's ten largest holdings make up 72% of its $645M portfolio in Q3 2021.
  • MPM BioImpact opened 19 new positions and closed 0 in Q3 2021.
  • MPM BioImpact's portfolio value rose 5.9% quarter-over-quarter to $645M.

Based on MPM BioImpact's 13F filing for Q3 2021, filed 15 Nov 2021.